Isturisa® (osilodrostat) – New orphan drug approval
March 6, 2020 - The FDA announced the approval of Recordati’s Isturisa (osilodrostat), for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
Download PDF
